---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-067651"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:48:39.493880+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corbus reports Phase 1 data for CRB-701 at ASCO: 44% ORR in mUC, 43% in cervical cancer

## Summary
- 44% ORR and 78% DCR in mUC (n=9), 43% ORR and 86% DCR in cervical cancer (n=7) at doses ≥1.2 mg/Kg.
- No DLTs or grade 4/5 AEs observed to date; single grade 1 neuropathy (resolved) and 3 skin rashes (resolved).
- Free MMAE levels lower than enfortumab vedotin across all doses up to 4.5 mg/Kg.
- Enrollment expanded to 37 patients (25 evaluable); US phase 1 completing Q4 2024, data Q1 2025.
- Preventative eye measures introduced after two grade 3 corneal disorders; no further cases at 4.5 mg/Kg.

## SEC filing metadata
- accession: 0000950170-24-067651
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024067651/0000950170-24-067651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024067651/crbp-20240601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-067651
- JSON: https://secwatch.observer/filing/0000950170-24-067651.json
- Plain text: https://secwatch.observer/filing/0000950170-24-067651.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.